DNLI - Biogen reports 11.16% passive stake in Denali Therapeutics
Biogen purchases ~13.3M shares of Denali Therapeutics (DNLI) on September 22.This represents 11.16% of total shares outstanding.The stake does not allow for activism.Press Release
For further details see:
Biogen reports 11.16% passive stake in Denali Therapeutics